Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Sept. 3, 2024 - Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference Read
- Aug. 6, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 1, 2024 - Puma Biotechnology Reports Second Quarter Financial Results Read
- July 18, 2024 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results Read
- July 2, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 7, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 3, 2024 - Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer Read
- June 2, 2024 - Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) Read
- May 28, 2024 - Puma Biotechnology to Join Russell 3000 Index Read
- May 23, 2024 - Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting Read
- May 2, 2024 - Puma Biotechnology Reports First Quarter Financial Results Read
- April 18, 2024 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results Read
- April 3, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Mar. 20, 2024 - Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer Read
- Feb. 29, 2024 - Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results Read
- Feb. 27, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Feb. 22, 2024 - Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference Read
- Feb. 15, 2024 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results Read
- Feb. 13, 2024 - Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer Read
- Jan. 11, 2024 - Puma Biotechnology to Present at B. Riley Securities 4 th Annual Oncology Conference Read